key: cord-0849606-pej3ozj9 authors: Mahmoudi, Samira; Dehkordi, Mehrdad Mohammadpour; Asgarshamsi, Mohammad Hossein title: The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects date: 2022-05-12 journal: Biophys Chem DOI: 10.1016/j.bpc.2022.106824 sha: 9bd4f38374853f1b7d2be1f123196503b959b25e doc_id: 849606 cord_uid: pej3ozj9 The novel coronavirus that caused COVID-19 pandemic is SARS-CoV-2. Although various vaccines are currently being used to prevent the disease's severe consequences, there is still a need for medications for those who become infected. The SARS-CoV-2 has a variety of proteins that have been studied extensively since the virus's advent. In this review article, we looked at chemical to molecular aspects of the various structures studied that have pharmaceutical activity and attempted to find a link between drug activity and compound structure. For example, designing of the compounds which bind to the allosteric site and modify hydrogen bonds or the salt bridges can disrupt SARS-CoV2 RBD–ACE2 complex. It seems that quaternary ammonium moiety and quinolin-1-ium structure could act as a negative allosteric modulator to reduce the tendency between spike-ACE2. Pharmaceutical structures with amino heads and hydrophobic tails can block envelope protein to prevent making mature SARS-CoV-2. Also, structures based on naphthalene pharmacophores or isosteres can form a strong bond with the PLpro and form a π-π and the Mpro's active site can be occupied by octapeptide compounds or linear compounds with a similar fitting ability to octapeptide compounds. And for protein RdRp, it is critical to consider pH and pKa so that pKa regulation of compounds to comply with patients is very effective, thus, the presence of tetrazole, phenylpyrazole groups, and analogs of pyrophosphate in the designed drugs increase the likelihood of the RdRp active site inhibition. Finally, it can be deduced that designing hybrid drug molecules along with considering the aforementioned characteristics would be a suitable approach for developing medicines in order to accurate targeting and complete inhibition this virus. The crystal structure of SARS-COV-2 spike receptor-binding domain [RBD] complexed with peptidase domain of ACE-2 is identified in detail (20, 21) . Specifically, SARS-CoV-2 is a beta coronavirus, having similarities with SARS-CoV virus, in binding with human ACE2 receptor and spike glycoprotein for viral entry (22) . The Spike domain is cleaved by furin protease into S1 and S2; the S1 domain binds to the ACE2 receptor attachment site. RBD is the short immunologic fragment of the S1 region including J o u r n a l P r e -p r o o f residues 318 to 510, which enables it to bind to the peptidase domain of ACE2. It contains a core including a twisted five-stranded anti-parallel β sheet including β1 to β4 and β7, with three short connecting α helices containing αA to αC and an extended loop. It was reported that in SARS-CoV-2 Delta variants the overall structure of this immunologic fragment has been strictly preserved among all variants, and reoccurring surface mutations appear to be limited to several sites, consistent with its critical role in receptor binding. Thus, it is best to focus on this part of the spike to design a novel drug (23) . Indeed, the receptor-binding motif (RBM) has a high degree of structural plasticity to hold amino acid changes without distracting ACE2 binding (24) . There are few variations at the RBM that considerably alter the binding affinity of RBD to the ACE2 in SARS-CoV2 (25, 26) . To stabilize the β sheet structure, there are nine cysteines in the chymotryptic fragment in the core; disulfide bonds connect cysteines 323 to 348, 366 to 419, 467 to 474 and 378 to 511 (20) .In the core, between the β4-7 strands, there is a gently concave outer surface formed by a twostranded β sheet (β 5 and β 6). This extended loop subdomain lies at one edge of the core where the RBM is, which contains the contacting residues that enable it to bind to N-terminal helix of ACE2. The RBM is particularly tyrosine-rich which present both a polar hydroxyl group and a hydrophobic aromatic ring. Multiple tyrosine residues form hydrogen-bonding interactions with the polar hydroxyl group. Thus, the networks of hydrophilic interactions which occur largely among amino acid side chains are seen in the RBM region (20) . According to the study conducted by Cong Xu et al., five tyrosine residues including (tyrosine 454,473,489,495,505) showed a vital role in the interactions of spike and ACE2 (27) . The salt bridges are important for SARS-CoV-2 RBD-ACE2 interaction. for example, it was reported that in the UK variant" (B.1.1.7) of SARS-CoV-2, the loss of salt bridges between Lys417 and ACE2 Asp30 and Glu484 and ACE2 Lys31 moderate in the increased receptor affinity imparted by N501Y (31) . It was recognized in the pathogenesis of the SARS-CoV-2 virus that SARS-CoV-2 RBD is located between residues Thr333-Gly526 of the S1 domain, which enables it to bind to ACE2 more strongly than SARS-CoV which may show the higher infectiousness of SARS-CoV-2 compared to SARS-CoV. Indeed, it appears that N-linked glycan at position Asn 90 of ACE2 bind to different RBDs and interferes with the infection of the cells (20) . The UK variant" (B.1.1.7) of SARS-CoV-2 is thought to be more infectious than previously circulating strains as a result of N501Y mutation that shows tyrosine 501 inserted into a cavity at the binding interface near tyrosine 41 of ACE2 using hydrophobic interactions with other aromatic side-chains of tyrosine 41. The aromatic side chain of tyrosine 501 can also mean that tyrosine is involved in possible cation-π interaction with ACE2 Lys353. This additional interaction provides a structural explanation for the increased ACE2 affinity of the N501Y mutant and likely contributes to its increased infectivity (31, 32) . the coupling of spike with ACE2 (35) . They showed that N-Acetyl-β-Glucosamine (NAG) specific binding site is site proximity to the hACE2-spike binding domain. It was considered that N-linked glycan at position Asn 90 is a competitor binder and reference ligand for the ACE2 protein target, thus, researchers hypnotized that NAG specific binding site occupation with ACEIs may impact the binding mode of the spike protein (36) and investigated the binding mode of ACEIs to the NAG-specific binding site through a molecular docking strategy. Finally, Alacepril and lisinopril exhibited the best binding affinity through forming a strong hydrogen bond with Asn90, as well as significant extra interactions with other receptorbinding residues (36) . The use of ACE inhibitors for the treatment of SARS-COV-2 has been controversial. Many studies find it useful and many useless (37) (38) (39) . Although Tipnis et al. in human homology study of ACE in 2000 showed that ACE inhibitors could not block ACE--2 (40) . Indeed, in 2021, M. Oz et al. showed that ACE inhibitors could increase ACE2 expression in RAAS (41) . Then, Imane Abdelli et al. in their studies focused on the co-crystallized inhibitor of ACE2 i.e. β-D-mannose using Isothymol, Thymol, Limonene, P-cymene, and γ-terpine. And Isothymol binding energy was calculated at -5.78 Kcal/mol and one hydrogen interaction with THR445 amino acids of the active site was recognized, on the other hand, the β-D-Mannose-binding energy was calculated at -5. 4107 Kcal/mol; in fact, 5 interactions with GLU406, GLU406, GLN442, GLN442, LYS441 residues of the target active site were observed, furthermore, the thymol binding energy was calculated at -4, 7450 Kcal/mol, and 2 interactions with GLU406 and THR445 were considered. The study revealed that Isothymol gives the best docking scores, compared to β-D-mannose and Captropil (42) . Furthermore, Hadjer Khelfaoui et al. proposed J o u r n a l P r e -p r o o f that there are two zinc-binding sites in the ACE2 receptor. This metallic ion facilitates the viral attachment to the surface of ACE2. Thus, docking of two active sites containing Zn 2+ in the ACE2 receptor and spike/ACE2 complex was chosen, then, they prepared the ACE2 receptor and spike/ACE2 complex and removed the NAG in their sequence. The results showed that Ramipril, Dalapril, and Lisinopril could bind with ACE2 receptors better than hydroxychloroquine and chloroquine (43) . Another study investigated the binding interactions of ivermectin, hydroxychloroquine, and remdesivir with human ACE-2 protein (PDB ID = 1R42) and compared it with MLN-4760 as the positive control. Docking results revealed that ivermectin had the highest binding affinity to the active site and it formed five hydrogen bonds with Arg273, Glu398, Ser511, Arg514, and Tyr515 amino acid residues present at the predicted active site. This was followed by remdesivir; it formed four hydrogen bonds with Asn394, Glu402, Glu406, and Arg514 amino acid residues present at the predicted active site. Also, MLN-4760 showed a high binding affinity by forming five H-bonds with Arg273, His345, Pro346, Thr37, and Tyr515 amino acid residues present at the predicted active site of the protein. It was notable that favipiravir achieved the lowest docking score in this study, hydroxychloroquine is bound to the human ACE-2 receptor with considerable binding force. It formed H-bonds with Arg273, Ala348, Glu375, and Arg514 amino acid residues (44) . Table 1 shows various ACE2 blockers, their chemical structures, interacting residues, and the docking software used. Negative allosteric modulation (NMA) occurs when the binding of one substance to the complex antagonizes the affinity of the stimulus to the active site (47, 48) . Regulation of spike-ACE2 attachment by binding an NMA at a site other than the ACE2 active site is a promising strategy to design novel drugs for COVID-19 treatment because when an NMA binds to spike protein fragments, a conformational change occurs and modifies the binding energy of ACE2 and spike protein complexes. Finally, the binding structure of ACE2 and spike A study analyzed the interactions of quinolin-1-ium derivatives such as hydroxychloroquine and chloroquine with SARS-CoV-2 using molecular docking studies. They confirmed that hydroxychloroquine acts as an NMA. It binds to the amino acids ASP350, ASP382, ALA348, PHE40, and PHE390 on the ACE2 allosteric site rather than on the ACE2 active site (51) . It seems that quaternary ammonium moiety builds a hydrogen bond with ASP382 and a π-cation interaction with aromatic amino acids such as PHE 390 with the spike protein fragments. In Quercetin showed π-π interaction with tyrosine 505 may block ACE2(26). As mentioned above, a main-chain hydrogen bond between the carbonyl of ACE2 Lys to an amide of RBD Gly fixes the relative positions of receptor and spike protein quite precisely. Accordingly, the compounds which have substituents that can form a salt bridge or a hydrogen bond with LYS 562, LYS95, or His 34 are promising compounds to block ACE2 (26) . In sum, it seems phytochemicals can disrupt the hydrophilic interaction of ACE2 and the receptor-binding domain. It seems that phytochemicals modulate the binding energy of the bound structure of ACE2 and spike. This result indicates that due to the presence of phytochemicals, the bound structure of ACE2 and spike protein fragment becomes unstable (21, 22) . Table 2 lists the compounds that target spike-ACE2 complex, their structures, and the important amino acids in the reaction between spike-ACE2 (26). This protein of SARS-CoV-2 is made up of 75 amino acids that are divided into two domains: a C-terminal domain and an N-terminal transmembrane domain (TMD) (52) . It is noteworthy that C-terminal has no stable complex, thus, its structures have not been well defined. N-terminus channel entrance and lumen are its targeted inhibitor binding sites. The narrowest part of this channel could be 2.6-4.8Å wide, with an average of 4.4Å (53) . The envelope is a protein with diverse tasks. It has a structural role in inducing membrane curvature for viral assembly in collaboration with the viral M protein, and it also mediates host immune responses by two distinct mechanisms: a PDZ (PSD-95/Dlg/ZO-1)-binding function via J o u r n a l P r e -p r o o f its C-terminal domain, and a pore-forming TMD associated with NLRP3 inflammasome activation (54, 55) . The TMD of the envelope structurally forms a pentameric ion channel (56) . In humans, each PDZ domain contains 80-110 amino acid residues and is required for the proper regulation of human immune responses (57) . SARS-CoV-2 hijacks PDZ-domain-containing proteins to increase virulence (57) . The SARS-CoV-2 envelope protein contains a PDZ-binding motif (PBM) at its C-terminus (58) . The exact mechanism is unknown, but interactions between a human cell junction protein (PALS1) and the PBM appear to show that the envelope causes PALS1 to be relocated from the cell junction to the endoplasmic reticulum-Golgi intermediate compartment site (ERGIC). In ERGIC, the envelope is localized and viral assembly occurs. Therefore, the PBM of envelope protein is involved in SARS-CoV-2 pathogenesis by binding the host's syntenin protein resulting in overexpression of inflammatory cytokines (59) . The SARS-CoV-2 envelope channel while embedding into the ERGIC/Golgi membranes can facilitate Ca2+ transport resulting in the activation of the NLRP3 inflammasome(57). It seems that the clinical utility of amantadine appears from its action as blocker of ion channels. Amantadine showed its antiviral effectiveness against influenza A with the inhibition of the M2 ion channel. It is also used for the treatment of Parkinson's Disease due to its low-potent noncompetitive inhibition of the NMDA receptor ion channel on striatal dopaminergic neurons (60) . Although there is no sequence homology between influenza A and SARS-CoV-2, amantadine inhibits two of the four known (3a and envelope proteins) or putative (Orf7b and Orf10) SARS- ion channels, which are more selective for monovalent cations than monovalent anions (61) . The conductivity preference is dependent on pH and the lipid constituents of the membrane. In physiological conditions, it appears to have a slight preference for cations (Na+, K+, Ca2+) (62, 63) . It seems that Amantadine can build π-alkyl interactions with another aromatic amino acid (64). Indeed, it seems that it can enter the ion channels and block them. The binding of amantadine to a synthetic TMD of envelope protein from SARS-CoV was significant enough (Kd~ 7mM) to completely block the ion conductance (53) . The simplest blocking mechanism for amantadine is that the cationic headgroup of amantadine is dragged into the channel by the electric field, and then occupied the channel with the hydrophobic group i.e., the adamantane group following and plugging the entry for the succeeding ions. A positively charged head group followed by a bulky hydrophobic scaffold might be the common structural feature of SARS-CoV-2 envelope protein inhibitors. Singh Tomar et al. proposed that a 3,5-dimethyl derivative of amantadine (memantine) which is the inhibitor of NMDA receptor can inhibit the SARS-CoV-2 ion channel. They specified that gliclazide which is the potassium currents blocker can inhibit the SARS-CoV-2 ion channel (65) . On the other hand, Amiloride derivatives (in particular hexamethylene amiloride) were found to be efficient inhibitors of envelope proteins of SARS-CoV-2 (66). Hexamethylene amiloride (HMA) like amantadine showed a positively charged headgroup and the bulky hydrophobic scaffold (67) . An investigation has demonstrated that the HMA inhibited in vitro conductance of J o u r n a l P r e -p r o o f synthetic MHV envelope and HCoV-229E envelope, which show close homology to SARS-CoV-2 envelope. They showed that a protonated form of HMA is bound to the channel (68) . To identify potential high-affinity blockers of the SARS-CoV-2 envelope channel, a screening study of approximately 6000 compounds was carried out by Chernyshev A as deposited in the ZINC database and their Vina score were compared. The study has revealed two siderophore iron chelators blocking the virus channel (53). Liu Wenzhong in his article demonstrated that Cys44 of envelope protein is the heme iron-linked site. Indeed, they showed that heme-linked sites of E protein may be relevant to the high infectivity. It can be seen that the first two Cys40, Cys43 on this domain are connected to the carbon at the left end of the alpha position and the beta position, respectively, and the last Cys44 is related to the iron of the heme (69) . Desferrioxamine and nocardamine are siderophore iron chelators that can chelate Ferric iron at a 1:1 stoichiometry. Their chemical structures are presented in Figure 3 . Overall, according to the Clifford Fong study, a predictive quantum mechanical TD DFT method is needed to describe the time-dependent behavior of inhibitors of the envelope ion channel of SARS-CoV-2. The key descriptors are the excitation energy of the first excited state of the inhibitor and the ground state HOMO-LUMO gap of the inhibitor that characterize the dynamic binding between the inhibitor and the protein target (70) . Different blockers of SARS-CoV-2 envelope protein ion channel, their chemical structures, and software used for docking are shown in Table 4 . inhibitors. It is noteworthy that the covalent inhibitor binds irreversibly to the receptor, while the non-covalent inhibitor binds reversibly to the receptor. Also, the tendency of a covalent inhibitor for binding to a target is stronger than that of a non-covalent inhibitor (82) . However, most covalent inhibitors are less attractive due to adverse drug responses, off-target side effects, toxicity, and lower potency but targeted covalent drugs have recently gained more attention. These drugs target a non-catalytic nucleophile that is unique for each target protein in contrast to the catalytic nucleophile in mechanism-based or suicide inhibitors (83, 84) . unappropriate PK profiles should be kept in mind when converting these to drug molecules (84) . It seems that a combination of peptide compounds that establish covalent bonds with Plpro and naphthalene-based compounds can be considered promising Plpro inhibitors. Disulfiram is Zn-ejector drug that can target highly conserved Zn 2+ -binding and/or catalytic cysteines (101) . As it is shown below in Figure 9 . Table 5 . The main protease (Mpro) of SARS-CoV-2 is a key enzyme and has a pivotal role in mediating viral replication and transcription, making it an attractive drug target for SARS-CoV-2 (103). Mpro, a cysteine protease, mediates the maturation cleavage of polyproteins during virus replication. Understanding the atomic-level mechanism of the peptide cleavage, catalyzed by cysteine proteases, is crucial for designing structure-based potent inhibitors. The protease-susceptible sites in a given protein or peptide usually extend to an octapeptide region in Mpro. Occasionally, the susceptible sites in some proteins may contain one subsite less or more. However, eight amino acid residues are the most common causes. Although the protein being cleaved contains much more than eight amino acid residues, usually only the segment of an octapeptide fits and extends in the active site region of Mpro. Therefore, drug design will focus on the cleavability of an octapeptide. First, the octapeptide fits well in binding to the Mpro active region leading to cleavage at its scissile bond, then, Gly143 of Mpro forms hydrogen bonds with ligands (104) The imidazole group of histidine polarizes and activates the SH group of the cysteine and forms a CysS−/HisH+ ion (His-Cys catalytic dyad) that has a high nucleophilic property that reacts with substrates (105) . Cysteine attacks the carbonyl carbon atom of the octapeptide after which the proton from the protonated HisH+ is transferred to the nitrogen atom of the scissile peptide bond. Therefore, the π bonding is broken and the covalent adduct is generated. Then the deacetylation stage is supposed to be assisted by a water molecule activated by histidine ( Figure 10 ) (104, 106, 107). According to the above, it seems that the design of peptidomimetic α-keto amid compounds is a synthetic strategy to produce broad-spectrum Inhibitors of SARS-CoV-2. The α-ketoamide is an unusual reactive proelectrophile and pronucleophile moiety, displaying two possible nucleophilic reaction sites together with two electrophilic centers(108). α-keto amid compounds match the Hbonding donor/acceptor properties of the catalytic center by offering two hydrogen-bond acceptors instead of one better than another compound such as aldehydes, α,β-unsaturated esters, and Michael acceptors (109) . In fact, the α-keto group of the compounds forms hydrogen bonds in the catalytic dyad to establish, and then another carbonyl carbon atom is attacked (110) . Finally, it seems that all potent SARS-CoV-2 Mpro inhibitors contain α-ketoamide reactive warheads (boceprevir ) (111). ) Figure 11 ( The α-ketoamide moiety has been considered for its ability to adjust the conformation of lead compounds by increasing or decreasing their structural rigidity or by conferring the capacity to establish hydrogen bonds, in order to improve their potency and pharmacokinetic profile (108) . In some compounds, aldehyde bisulfate warhead and vinyl sulfone were replaced with keto group (Figure 13) , indeed, instead of polarized nitrogen, there should be aromatic groups such as styrene not to break during the deacetylation reaction (111, 113) . Journal Pre-proof Figure 13 . the reaction mechanism between vinyl sulfone and thiol moiety of cystein group. On the other hand, some articles proposed that fluorinated ketone moiety could be utilized as a warhead for targeting proteases, because it forms a thermodynamically stable hemiketal or hemithioketal after nucleophilic attack by Ser-OH or Cys-SH residues, which are present in the active sites of serine or cysteine proteases, respectively (114) (115) (116) (117) (118) . (Figure 14 ) probably because, the more rigid lactam leads to a reduction of the loss of entropy upon binding to the target protease (110) . The studies showed that the γ-lactam ring can fill the S1 site of M pro. To improve the half-life of the compound in plasma, the amide bond within needs to be modified with a pyridone ring. This might prevent cellular proteases from accessing this bond and cleaving it. This compound showed favorable pharmacokinetic results. It seems administration of nebulized pyridone-containing α-ketoamides to the lungs would be possible (109) . In a research, to increase the solubility of the compound in plasma and to reduce its binding to plasma proteins, they added hydrophobic groups for example they replaced the hydrophobic cinnamoyl moiety with the somewhat less hydrophobic tert-Butyloxycarbonyl protecting (Boc) group. The studies showed that Boc group is necessary to enter the cells. Cyclohexyl moiety in these structures can fill the S2 pocket and produce broad-spectrum inhibitors. Indeed 3 fluro-phenyl can be replaced with cyclohexyl moiety and can increase lung tropism (116, 119) . The synthetic strategy to produce inhibitors of SARS-CoV-2 Mpro is presented in Figure 15 . J o u r n a l P r e -p r o o f The Mpro active site contains a catalytic dyad in which a cysteine residue (Cys145) acts as a nucleophile, and histidine residue (His41) acts as a base (121) . Cys145 is a chemical species that form bonds with electrophiles by donating an electron pair. Cysteine thiol is a highly reactive moiety due to its high electron density and polarizability and can, therefore, be targeted by less reactive ligands i.e cysteine-targeted electrophiles such as vinyl sulfones, epoxides, isothiazolones, and ketoamides. It seems that ketoamide groups of boceprevir and telaprevir can react covalently with cysteine thiol moiety of COVID as well as Hepatitis C virus (HCV) protease which is also targeted covalently by these drugs (122) . Indeed, cyclopropanesulfonamide moiety in Paritaprevir and Simeprevir can be targeted by cysteine residue (Cys145) (123) . In a study conducted by Duc Duy Nguyen et.al, They concluded that the strongest bond is formed between the boronic acid moiety of bortezomib(lewis acid ) and Cys 145(base) (124) . On the other hand, it seems that Mpro histidine has a positively charged imidazole functional group. The unprotonated imidazole is nucleophilic and can serve as a general base. Thus, compound 621 can produce cation-π interaction with His 41(125). and the morpholine ring of ZINC03231196 was formed. Compound ZINC33173588 exhibited a J o u r n a l P r e -p r o o f Journal Pre-proof ππ T-shaped bond with a first benzene ring and His41, in fact, two π -alkyl bonds were formed between amino acids Cys145, His41, and morpholine ring (126) . It was described that SARS-CoV-2 Mpro is a target for Atazanavir. Atazanavir could inhibit viral replication in cell culture models of infection that also prevented the release of a cytokine storm-associated mediators. The appropriate binding of Atazanavir, suggested by its lower energy score, may be related to its projected ability to form hydrogens bonds with the amino acid residues Asn142, His164, and Glu166 in Mpro (16) . Table 6 . The virus RdRp, which, as previously stated, plays an important role in the transcription and replication of the SARS-CoV-2, is known as nsp12 (135, 136) . Other cofactors for nsp12 in polymerase activities are nsp7 and nsp8, and RdRp would not have much catalytic activity without them. As a result, the RdRp active unit is made up of an nsp7-nsp8 heterodimer, an nsp12 nucleus catalytic unit, and an extra nsp8 subunit (137) . The RdRp active site is composed of seven conserved catalytic motifs (motifs A to G). Motifs A to E is in the palm subdomain, while motifs F and G are in the finger subdomain (138) . The catalytic motif DX2-4D is found in motif A (139) . Also, the first aspartic acid 618 in this motif is invariant in most viral polymerases (140) . In motif B, there is a flexible loop that acts as a hinge to take the arrangement of configuration related to substrate binding and template RNA (140) . Residues phenylalanine753 to aspargine767 are Motif C which contains the catalytic motif SDD. Motif SDD is from residues serine759 to aspartic acid761 and is necessary for the attachment of the metal ion (139) . Aspartic acid760 and aspartic acid761 in the RdRp structures also are in charge of two magnesium ions' coordination at the catalytic center (140) . the conserved aspartic acids in catalytic motifs DX2-4D and SDD determine catalytic activity (141) . Residues from leucine544 to valine 557 are Motif F which interacts with the phosphate group of incoming NTP (140) . Also, residues from aspartic acid 499 to leucine 514 are Motif G that interacts with the RNA J o u r n a l P r e -p r o o f template strand and probably can take it to the active catalytic site (142) . It seems that the active catalytic motifs of the RdRp are highly conserved in most SARS-CoV-2 strains, therefore, RdRp is another promising drug target (140) . Remdesivir (RDV, GS-5734) is a pro-drug that is a 1'-Ribose cyano substitution of adenosine nucleotide analog. Its adenine fragment is modified, and The presence of a cyano group at the anomeric carbon is unusual, and it leads to a lower activity on mammal RNA polymerases (102) . The ionizable groups of these compounds are blocked by lipophilic moieties, allowing a good membrane permeability (102) . Different blockers of SARS-CoV-2 RdRp, their chemical structures, and the software used for docking are shown in Table 6 . In this article, we first review the latest life cycle findings of the SARS-CoV-2 and its important proteins that contribute to infection. Then, we surveyed the various structures that could have pharmaceutical activity and tried to find a structure-activity relationship (SAR). To study the various structure against SARS-CoV-2, the molecular docking approaches have been applied to model the interaction between small molecules and various proteins of SARS-CoV-2 at the atomic level to characterize the behavior of different molecules such as repurposed drugs in the binding site of target proteins and to elucidate the ligand conformation, its docking pose, and assessment of the binding affinity (149) . As many of these studies were performed with different molecular docking software, the amount of binding energy could not be compared precisely. Also, many drugs showed an appropriate docking pose, but may not turn into their active structure in the body. Indeed, in vitro and in vivo studies are also required to know if the compounds that have been identified can inhibit COVID19 infection in a human host. One approach to treat COVID-19 is regulating the spike-ACE2 complex by the negative allosteric modulators. (150, 151) . In the beginning, SARS-CoV-2 RBD-ACE2 interface was investigated precisely. Then, studies were investigated to find some molecules that can compete with the spike to attach to the receptor. Antihypertensive drugs that block ACE receptors are the most well-known of these drugs. According to many studies, three different docking methods have been used on the receptor, but it has yet to be determined which docking method is the most The compounds which affected the voltage-gated ion channel of influenza and NMDA receptors seem to be effective on the channel structures of SARS-CoV-2, allowing drugs like adamantine derivative to block channels in the virus envelope. It seems that the structures with amino heads and hydrophobic tails can block envelope protein, and amine heads can react with hydrogen and metal ions to produce quaternary amines, and then, they are placed at the envelope's gate, while hydrophobic tails can block the receptor. Also, according to the virtual screening studies in data banks, siderophores have been identified as a potential channel blocker for the envelope of SARS-CoV-2 because they have the ability to chelate the metal ions. As mentioned above, Heme-linked sites of the E protein (Cys44) may be relevant to the high infectivity (69) . Desferrioxamine and nocardamine are siderophore iron chelators that can chelate Ferric iron at a 1:1 stoichiometry to inhibit iron to bind to the hemeiron linked site of E. Indeed, a predictive quantum mechanical TD-DFT method should be needed to describe the time-dependent behavior of these inhibitors (70) . It seems the synthesis of a naphthalene-based scaffold which can covalently bind to cysteine would be an effective strategy to antagonize the PLpro structure. Docking studies on naphthalene-based structures or their isosteres have shown that they can create a π-π interaction J o u r n a l P r e -p r o o f with the PLpro structure. Cysteine is an important amino acid in the PLpro structure because it attacks the positive charge centers in drugs, allowing cysteine to participate in nucleophilic reactions, addition, and the formation of a covalent bond between the drug and the receptor (152) . Regarding the Mpro's active site, it can be occupied by octapeptide compounds or linear compounds with a similar fitting ability to octapeptide compounds. Mpro also has a flexible structure that allows it to accommodate compounds as large as one or more amino acids. The positive charge center of the peptide structure is on the carbonyl groups. To increase the positive charge on carbon, pharmacodynamic studies have been conducted extensively. For example the carbonyl groups could be replaced with vinyl sulfone, aldehyde bisulfate, or fluorinated ketone groups. In fact, gamma-lactam rings, for example, are frequently substituted for carbonyl groups. Besides, some studies, have attempted to design drugs by adding non-polar and aromatic groups to the compounds in order to reduce the amount of drug-protein binding in the blood and the volume of distribution in the body while also increasing the drug's tropism within the lungs (153) . It is worth noting that virtual screening of potential Mpro inhibitors has also confirmed that Lewis acid structures such as bortezomib, which contains boron metal bind to M-protein with ease (154) . Various studies have shown that a key difference between RdRp and other targets is that RdRp is more polar, and many drugs must make a salt bridge with RdRp active site amino acids. Thus, the pKa of the desired compound is important to work in the active site because these compounds need to take hydrogen ions at this pH, so they can't enter the active site and form a salt bridge or hydrogen bond. Another point to consider is that the pKa of the designed drugs should be regulated to comply with patients; for example, extravasations of remdesivir into the perivascular environment due to its acidic structure will cause erythema in the vessels and skin J o u r n a l P r e -p r o o f of patients (146, 155 , and PHE140, two alkyl interactions with MET49 and MET165, and three πsystem•••alkyl interactions with HIS41 and CYS145. It seems that one of the π-system•••alkyl interactions for all the tautomers with Mpro is formed by the π-system of the ligands (157) . ( Figure 19 ) Asp289 and interaction of the Amide-π stacked type with Thr198. They used the modern concept of hydrogen bonds (159) . Despite the conventional constant of hydrogen bond, the nature of the interaction is not constant, but its electrostatic, covalent, and dispersion contributions vary in their relative weights. The hydrogen bond has broad transition regions that merge continuously with the covalent bond, the van der Waals interaction, the ionic interaction, and also the cation-π interaction (160) . According to this theory, the hydrogen bond length of 2.2-2.5 Å is indicated as a strong covalent bond. They showed the interaction of baricitinib (and Finally, it can be concluded that one of the challenges in designing drugs is that the coronavirus has genetic mutations and drug resistance that cause the treatment protocols to change easily (162) . Therefore, it would be best to add the appropriate pharmacophores to a new molecule considering the structures and points mentioned for each protein, and then, design a new hybrid molecule to increase the drug's effectiveness against genetic mutations (163, 164) . For example, hydroxychloroquine and adamantane based hybrids were synthesized by Lars Herrmann et.al, but due to the QT-prolongation problems; hydroxychloroquine hybrids couldn't be considered. Indeed they have shown the positive effects of Artemisinin on SARS-CoV-2. So the hybrid based on Artemisinin derivatives, Quinoline, or adamantane moieties was synthesized (163, 165) . Other studies have shown the anti-viral activity of isothiourea, and adamantane derivatives. in 2017; the isothiourea and adamantane based hybrids were synthesized J o u r n a l P r e -p r o o f but their activity against SARS-CoV-2 has not been measured yet (166) . Further; as mentioned above the active form of remdesivir showed high polarity so to improve their pharmacokinetic profile it could be better to fuse the remdesivir active form with other pharmacophores in a single multi-functional agent. None Corona virus-related Disease Pandemic: A Review on Machine Learning Approaches and Treatment Trials on Diagnosed Population for Future Clinical Decision Support. Current Medical Imaging COVID-19: a global challenge with old history, epidemiology and progress so far Estimating infectiousness throughout SARS-CoV-2 infection course SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants The novel drug discovery to combat COVID-19 by repressing important virus proteins involved in pathogenesis using medicinal herbal compounds The polybasic cleavage site in SARS-CoV-2 spike modulates viral sensitivity to type I interferon and IFITM2 Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (Mpro) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease COVID-19: comprehensive review on mutations and current vaccines The reproductive number of COVID-19 is higher compared to SARS coronavirus Genetic variation in SARS-CoV-2 may explain variable severity of COVID-19 Coronavirus disease (COVID-19): Current status and prospects for drug and vaccine development. Archives of medical research Efficacy and safety of new and emerging drugs for COVID-19: Favipiravir and Dexamethasone Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors. Informatics in medicine unlocked Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production COVID-19: Drug Targets and Potential Treatments Drug targets for corona virus: A systematic review Potential drug targets of SARS-CoV-2: From genomics to therapeutics Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Structure of SARS coronavirus spike receptor-binding domain complexed with receptor Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2 Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity Screening of potential spike glycoprotein / ACE2 dual antagonists against COVID-19 in silico molecular docking Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM Receptor and viral determinants of SARScoronavirus adaptation to human ACE2 A trimeric human angiotensinconverting enzyme 2 as an anti-SARS-CoV-2 agent A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2 Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study Angiotensin-converting enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in coronavirus disease 2019 Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor ACE inhibitors and COVID-19: we don't know yet Controversy regarding ACE inhibitors/ARBs in COVID-19 Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people A human homolog of angiotensinconverting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2 Abdel-Moneim AS. Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2 In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria Molecular docking and dynamics simulation revealed the potential inhibitory activity of ACEIs against SARS-CoV-2 targeting the hACE2 receptor Negative allosteric modulation of GluN1/GluN3 NMDA receptors The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study Structural basis for SARS-CoV-2 envelope protein recognition of human cell junction protein PALS1 Pharmaceutical targeting the envelope protein of SARS-CoV-2: the screening for inhibitors in approved drugs SARS-CoV-2 Envelope Protein Induces Membrane Curvature through Asymmetric Hydrophobic Mismatch: Rutgers, The State University of Host PDZ-containing proteins targeted by SARS-CoV-2. The FEBS journal In silico identification of Tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor. Computers in biology and medicine Structural basis for SARS-CoV-2 envelope protein recognition of human cell junction protein PALS1 Comparing the binding properties of peptides mimicking the Envelope protein of SARS-CoV and SARS-CoV-2 to the PDZ domain of the tight junction-associated PALS1 protein Host-membrane interacting interface of the SARS coronavirus envelope protein: Immense functional potential of C-terminal domain Could amantadine possibly interfere with COVID-19 vaccines based on LNP-mRNA platform ? SARS coronavirus E protein forms cation-selective ion channels Amantadine inhibits SARS-CoV-2 in vitro Amantadin has potential for the treatment of COVID-19 because it targets known and novel ion channels encoded by SARS-CoV-2. 2020. 64. Baig AM, Khaleeq A, Syeda H. Docking Prediction of Amantadine in the Receptor Binding Domain of Spike Protein of SARS-CoV-2 SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis? Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication Structure and inhibition of the SARS coronavirus envelope protein ion channel Flawed methods in "COVID-19: attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism Inhibition of SARS-CoV-2 envelope ion channel and the relationship with the membrane dipole potential SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates Potential for the Repurposing of Adamantane Antivirals for COVID-19 Docking and molecular dynamics (MD) simulations in potential drugs discovery: an application to influenza virus M2 protein A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem) Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus An overview of potential inhibitors targeting non-structural proteins 3 (PLpro and Mac1) and 5 (3CLpro/Mpro) of SARS-CoV-2 Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase Targeting severe acute respiratory syndromecoronavirus (SARS-CoV-1) with structurally diverse inhibitors: a comprehensive review Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. The EMBO journal Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus Geometric characteristics of hydrogen bonds involving sulfur atoms in proteins Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design. Science advances Structural biology of SARS-CoV-2 and implications for therapeutic development MD-2 as the target of curcumin in the inhibition of response to LPS Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs Molecular recognition with boronic acids-applications in chemical biology Molecular recognition with boronic acids-applications in chemical biology Gliptin repurposing for COVID-19 The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds Structure-based drug designing of naphthalene based SARS-CoV PLpro inhibitors for the treatment of COVID-19 Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors Structural basis of potential inhibitors targeting SARS-CoV-2 main protease Attack of zwitterionic ammonium thiolates on a distorted anilide as a model for the acylation of papain by amides. A simple demonstration of a bell-shaped pH/rate profile Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of the octapeptide Prediction of human immunodeficiency virus protease cleavage sites in proteins The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease Characterization and inhibition of the main protease of severe acute respiratory syndrome coronavirus A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells. bioRxiv : the preprint server for biology Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α Reevaluation of the strain energies of cyclopropane and cyclobutane carbon-carbon and carbonhydrogen bond energies, 1, 3 interactions, and. sigma.-aromaticity The recent outbreaks of human coronaviruses: A medicinal chemistry perspective First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery Pseudo-Dipeptide Bearing α,α-Difluoromethyl Ketone Moiety as Electrophilic Warhead with Activity against Coronaviruses Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease Substrate Specificity Profiling and Identification of a New Class of Inhibitor for the Major Protease of the SARS Coronavirus Plant Products as Inhibitors of Coronavirus 3CL Protease Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDAapproved inhibitors of SARS-CoV-2 main protease 3CLpro Sulfonyl vs. carbonyl group: which is the more electron-withdrawing? Chemical Communications Potentially highly potent drugs for 2019-nCoV Pharmacoinformatics and molecular dynamic simulation studies reveal potential inhibitors of SARS-CoV-2 main protease 3CLpro Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening Telaprevir is a potential drug for repurposing against SARS-CoV-2: Computational and in vitro studies Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. ACS medicinal chemistry letters Analysis of the molecular activity of atazanavir against SARS-COV-2 by molecular docking studies Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Computational and structural biotechnology journal Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery. Computers in biology and medicine In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19 Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease Computational simulations on the binding and reactivity of a nitrile inhibitor of the SARS-CoV-2 main protease Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease Structural biology of the SARS-CoV-2 replisome: evolutionary and therapeutic implications RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. Biochemical and biophysical research communications SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A review Structural basis for RNA replication by the SARS-CoV-2 polymerase Polyamidoamine-Remdesivir Conjugate: Physical Stability and Cellular Uptake Enhancement Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase SARS-CoV-2: Origin, Evolution, and Targeting Inhibition Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2. Molecular Diversity Tetrazole and triazole as bioisosteres of carboxylic acid: Discovery of diketo tetrazoles and diketo triazoles as anti-HCV agents Epidemiology, virology, clinical features, diagnosis, and treatment of SARS-CoV-2 infection Molecular docking: a powerful approach for structurebased drug discovery Prophylactic (hydroxy) chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk QTc interval prolongation, COVID-19 and chloroquine Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay Theoretical Evaluation of Bortezomib and Other Boron-Containing Compounds as Inhibitors of SARS-CoV-2 Main Protease Painful blisters of left hand following extravasation of remdesivir infusion in COVID-19. Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis Computational Analysis of Molnupiravir Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease The hydrogen bond in the solid state A Lewis acid-promoted Pinner reaction A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity Artemisinin and Quinoline Hybrid Compounds Inhibit Replication of SARS-CoV-2 In Vitro COVID-19 Drug Design Based on the Active Core of Well-known Anti-malarial: A computational QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review Adamantane-Isothiourea Hybrid Derivatives: Synthesis, Characterization The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects Highlights: Studying different druggable targets for SARS-CoV-2 infection.  How hybrid drug molecules can be designed by considering effective and suitable chemical structures for inhibiting the main proteins of the virus at the same time.  Surveying regulation of spike-ACE2 by binding a negative allosteric modulator at the allosteric site of ACE2.  Looking at chemical to molecular aspects of the various structures with pharmaceutical activity on COVID.J o u r n a l P r e -p r o o f